Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
QSOX1 is an enzyme that catalyzes the oxidation of sulfhydryl groups in peptide and protein thiols to form disulfide bonds, with the concomitant reduction of molecular oxygen to hydrogen peroxide. It contains both an ERV family module and a thioredoxin domain. Its expression increases as fibroblasts exit the cell cycle into quiescence and it contributes to extracellular matrix assembly and normal cell-cell adhesion and migration. It is upregulated in certain cancers and has been implicated in sorafenib-induced ferroptosis in hepatocellular carcinoma.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Quiescin Sulfhydryl Oxidase 1 (QSOX1).